Table 1. Baseline characteristics of the patients according to the PDW.
| Variables | Totaln (%) | PDW ≤ 16.8n (%) | PDW > 16.8n (%) | P value |
|---|---|---|---|---|
| Age (years) | 0.036 | |||
| ≤60 | 197 (67.0) | 48 (57.8) | 149 (70.6) | |
| >60 | 97 (33.0) | 35 (42.2) | 62 (29.4) | |
| Gender | 0.602 | |||
| Male | 206 (70.1) | 60 (72.3) | 146 (69.2) | |
| Female | 88 (29.9) | 23 (27.7) | 65 (30.8) | |
| T stage | < 0.001 | |||
| T1 | 28 (9.5) | 4 (4.8) | 24 (11.4) | |
| T2 | 58 (19.7) | 18 (21.7) | 40 (18.9) | |
| T3 | 84 (28.6) | 27 (32.5) | 57 (27.0) | |
| T4 | 124 (42.2) | 34 (41.0) | 90 (42.7) | |
| N stage | 0.013 | |||
| N0 | 79 (26.9) | 18 (21.7) | 61 (28.9) | |
| N1 | 54 (18.4) | 12 (14.4) | 42 (19.9) | |
| N2 | 74 (25.2) | 20 (24.1) | 54 (25.6) | |
| N3 | 87 (29.6) | 33 (39.8) | 54 (25.6) | |
| Cancer Stage | < 0.001 | |||
| I | 40 (13.6) | 10 (12.0) | 30 (14.2) | |
| II | 88 (29.9) | 22 (26.5) | 66 (31.3) | |
| III | 148 (50.3) | 40 (48.2) | 108 (51.2) | |
| IV | 18 (6.1) | 11 (13.3) | 7 (3.3) | |
| Tumor Size | 0.360 | |||
| ≥ 5cm | 88 (29.9) | 31 (37.3) | 67 (31.8) | |
| < 5cm | 206 (70.1) | 52 (62.7) | 144 (68.2) | |
| Histology differentiation | 0.801 | |||
| Well/moderately | 54 (18.4) | 16 (19.3) | 38 (18.0) | |
| Poorly | 240 (81.6) | 67 (80.7) | 173 (82.0) | |
| CEA (ng/ml) | 0.009 | |||
| < 5 | 240 (81.6) | 60 (72.3) | 180 (85.3) | |
| ≥ 5 | 54 (18.4) | 23 (27.7) | 31 (14.7) | |
| NLR | 0.080 | |||
| ≤ 2.39 | 186 (63.3) | 46 (55.4) | 140 (66.4) | |
| > 2.39 | 108 (36.7) | 37 (44.6) | 71 (33.6) | |
| PLR | 0.082 | |||
| ≤ 176.6 | 196 (66.7) | 49 (59.0) | 147 (69.7) | |
| > 176.6 | 98 (33.3) | 34 (41.0) | 64 (30.3) |
PDW, platelet distribution width; CEA, carcinoembryonic antigen; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.